Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist.
Journal
Neurology. Clinical practice
ISSN: 2163-0402
Titre abrégé: Neurol Clin Pract
Pays: United States
ID NLM: 101577149
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
entrez:
13
3
2019
pubmed:
13
3
2019
medline:
13
3
2019
Statut:
ppublish
Résumé
To provide neurologists with an update on the proposed mechanisms of action (MOAs) of disease-modifying therapies (DMTs) for the treatment of relapsing MS, and their effect on peripheral blood leukocytes, in order to inform treatment decisions. DMTs have vastly differing MOAs, including effects on peripheral blood leukocyte counts, particularly lymphocytes. The clinical implications of changes in lymphocyte counts need to be understood in the context of the underlying MOAs of each respective DMT, with treatment tailored to individual patient needs. DMTs can alter lymphocyte counts, subsets, activation, and distribution, and thus can influence immune surveillance. Serial monitoring of total leukocytes and absolute lymphocyte counts (ALCs) is advisable in patients receiving DMTs. ALCs should be interpreted regarding expected immunologic changes and individual patient characteristics. Any decision to switch DMTs should consider these factors, along with drug efficacy, safety, and effect on quality of life.
Identifiants
pubmed: 30859008
doi: 10.1212/CPJ.0000000000000567
pii: NEURCLINPRACT2017023382
pmc: PMC6382377
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
53-63Commentaires et corrections
Type : ErratumIn
Références
N Engl J Med. 2000 Sep 28;343(13):938-52
pubmed: 11006371
J Neuroimmunol. 2000 Nov 1;111(1-2):86-92
pubmed: 11063825
J Clin Invest. 2002 Mar;109(5):641-9
pubmed: 11877472
Brain. 2002 May;125(Pt 5):952-60
pubmed: 11960885
J Biol Chem. 2002 Jun 14;277(24):21453-7
pubmed: 11967257
Brain. 2004 Sep;127(Pt 9):1970-8
pubmed: 15215217
Drug Saf. 2004;27(10):745-56
pubmed: 15350158
Neurology. 2005 Dec 27;65(12):1964-6
pubmed: 16380621
Arch Neurol. 2006 Oct;63(10):1383-7
pubmed: 17030653
Immunology. 2007 May;121(1):29-39
pubmed: 17239199
Blood. 2008 Apr 1;111(7):3893-5
pubmed: 18235044
N Engl J Med. 2010 Feb 4;362(5):387-401
pubmed: 20089952
N Engl J Med. 2010 Feb 4;362(5):402-15
pubmed: 20089954
Immunol Today. 1990 Nov;11(11):406-10
pubmed: 2078294
Aust Fam Physician. 2011 Dec;40(12):948-55
pubmed: 22146321
N Engl J Med. 2012 May 17;366(20):1870-80
pubmed: 22591293
Neurol Res. 2012 Sep;34(7):730-3
pubmed: 22709910
Lancet. 2013 Jun 22;381(9884):2167-75
pubmed: 23562009
Expert Opin Drug Metab Toxicol. 2013 Oct;9(10):1349-59
pubmed: 23795716
JAMA Neurol. 2013 Oct;70(10):1315-24
pubmed: 23921521
Neurology. 2013 Sep 3;81(10):872-6
pubmed: 23925762
Mult Scler. 2014 Apr;20(4):471-80
pubmed: 23950550
Clin Exp Immunol. 2014 Mar;175(3):425-38
pubmed: 24134716
J Immunol. 2013 Dec 15;191(12):5867-74
pubmed: 24198283
PLoS One. 2013 Nov 05;8(11):e78532
pubmed: 24223820
Clin Exp Immunol. 2014 Jun;176(3):320-6
pubmed: 24387139
Mult Scler. 2014 Jul;20(8):1074-80
pubmed: 24436455
Lancet Neurol. 2014 Jun;13(6):545-56
pubmed: 24685276
J Neurol Sci. 2014 Jun 15;341(1-2):22-7
pubmed: 24731783
Drugs. 2014 Apr;74(6):659-74
pubmed: 24740824
JAMA Neurol. 2014 Nov;71(11):1421-8
pubmed: 25264704
Neurology. 2014 Dec 2;83(23):2153-7
pubmed: 25361781
Ther Adv Neurol Disord. 2015 Jan;8(1):20-30
pubmed: 25584071
Neurology. 2015 Mar 3;84(9):872-9
pubmed: 25636714
Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(2):e70
pubmed: 25738167
Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(3):e76
pubmed: 25738172
Expert Rev Neurother. 2015 Jun;15(6):575-86
pubmed: 25924547
Lancet. 2015 Aug 22;386(9995):743-800
pubmed: 26063472
BMC Neurol. 2015 Jun 23;15:96
pubmed: 26099927
Int J Mol Sci. 2015 Jul 20;16(7):16414-39
pubmed: 26204829
Mult Scler Relat Disord. 2015 Sep;4(5):460-469
pubmed: 26346796
J Neurol Sci. 2015 Nov 15;358(1-2):22-30
pubmed: 26440421
Mult Scler J Exp Transl Clin. 2015 Jan-Dec;1:null
pubmed: 26550483
Front Immunol. 2015 Nov 05;6:565
pubmed: 26594215
Cent Eur J Immunol. 2015;40(3):354-9
pubmed: 26648781
Neurology. 2016 Mar 15;86(11):1014-21
pubmed: 26888980
Nat Rev Neurol. 2016 Apr;12(4):217-33
pubmed: 26943779
J Autoimmun. 2016 Jun;70:40-51
pubmed: 27055778
Neurol Neuroimmunol Neuroinflamm. 2016 Apr 29;3(3):e228
pubmed: 27213173
Neurol Clin Pract. 2016 Jun;6(3):220-229
pubmed: 27347439
Neurol Neuroimmunol Neuroinflamm. 2016 Aug 12;3(5):e275
pubmed: 27559542
Mult Scler Relat Disord. 2016 Sep;9:36-46
pubmed: 27645341
N Engl J Med. 2017 Jan 19;376(3):221-234
pubmed: 28002679
Neurology. 2017 Feb 28;88(9):816-817
pubmed: 28148634
EBioMedicine. 2017 Feb;16:41-50
pubmed: 28161400
Mult Scler. 2018 Feb;24(2):167-174
pubmed: 28273776
Mult Scler Relat Disord. 2017 Feb;12:59-63
pubmed: 28283109
Ther Adv Neurol Disord. 2017 Sep;10(9):327-336
pubmed: 28861122
Lancet Neurol. 2017 Nov;16(11):925-933
pubmed: 28969984
Mult Scler Relat Disord. 2018 Jan;19:105-108
pubmed: 29182993
Mult Scler Relat Disord. 2018 May;22:27-34
pubmed: 29524759
Neurology. 2018 May 15;90(20):e1815-e1821
pubmed: 29669908
Neurology. 2018 Apr 24;90(17):777-788
pubmed: 29686116
Mult Scler. 2018 Jul;24(8):1014-1022
pubmed: 29774781
Klin Wochenschr. 1974 Jun 1;52(11):511-5
pubmed: 4853392